Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) (ALZ-NET)
Brief description of study
The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect data from individuals evaluated for or receiving treatment with novel (or new) FDA-approved therapies for Alzheimer's disease (AD). It will follow and record information about people's health, safety, brain scans, and long-term health outcomes during their regular memory care.
Detailed description of study
ALZ-NET is a national, volunteer provider-enrolled longitudinal cohort registry designed to address key scientific and clinical questions on long term safety, clinical use and outcomes for patients being evaluated for or treated with novel FDA-approved therapies for AD. Treatments will be prescribed at the prescribing clinician’s discretion. Patients will be monitored by the treating clinician according to patient needs and local standard of care (SOC).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 18 years - 99 years
-
Gender: All
- Diagnosis of MCI or dementia with clinical suspicion of Alzheimer’s disease (AD) as contributing pathology and 1) is being evaluated for treatment or 2) will be initiating treatment or 3) has already initiated treatment with novel FDA-approved AD therapies in real world clinical practice
- Patient’s treating clinician has made the decision to provide clinical care or treatment prior to patient consent and independently of the purpose of ALZ-NET
- Patient or patient’s legally authorized representative (LAR) (e.g., spouse or legal guardian) has the ability to understand the purpose and risks of ALZ-NET and provide signed and dated informed consent and authorization to use protected health information (PHI)
Please choose between Voice or SMS based delivery of verification code
or